en
Scientific article
English

Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients

Published inNMCD. Nutrition Metabolism and Cardiovascular Diseases, vol. 19, no. 9, p. 613-619
Publication date2009
Abstract

BACKGROUND AND AIMS: Reduced high density lipoproteins (HDL) and increased oxidative stress are features of type 2 diabetes. Myeloperoxidase is an oxidative enzyme partly associated with HDL and causing HDL dysfunction. It is an independent risk factor for cardiovascular disease. Paraoxonase-1 is an HDL-associated enzyme that protects against cardiovascular disease and is reduced in diabetes. The present study examined if serum myeloperoxidase was (i) increased in type 2 diabetes, (ii) correlated with paraoxonase-1 activity. METHODS AND RESULTS: The study was based on cross-sectional analyses of serum myeloperoxidase and paraoxonase-1 in type 2 diabetic patients and non-diabetic participants, with and without cardiovascular disease. Serum myeloperoxidase concentrations were not increased in type 2 diabetic patients without cardiovascular disease compared to non-diabetic controls. They were significantly higher in type 2 patients and non-diabetic patients with angiographically confirmed coronary disease. HDL-associated myeloperoxidase was correlated with serum myeloperoxidase (r=0.80, p<0.001) but not HDL-cholesterol (r=0.08) or apolipoprotein AI (r=0.08). Multivariate analyses showed serum myeloperoxidase to be an independent determinant of paraoxonase activities (arylesterase, p=0.024; paraoxonase, p=0.026). CONCLUSIONS: Myeloperoxidase is an independent, negative determinant of paraoxonase-1 activity, which may be one mechanism by which it promotes HDL dysfunction and increases cardiovascular risk. Increased serum myeloperoxidase is not a feature of type 2 diabetes in the absence of overt cardiovascular disease. The level of HDL-associated myeloperoxidase is determined by the serum concentration of the enzyme suggesting that, in the context of reduced HDL concentrations in diabetic patients, myeloperoxidase may have a greater impact on HDL function.

Keywords
  • Adult
  • Aged
  • Apolipoprotein A-I/blood
  • Aryldialkylphosphatase/*blood
  • Coronary Artery Disease/blood/epidemiology
  • Cross-Sectional Studies
  • Diabetes Mellitus, Type 2/*blood/*epidemiology
  • Enzyme Activation/physiology
  • Female
  • Humans
  • Lipoproteins, HDL/blood
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Oxidative Stress/*physiology
  • Peroxidase/*blood
  • Predictive Value of Tests
  • Risk Factors
Citation (ISO format)
JORNAYVAZ, François, BRULHART-MEYNET, Marie-Claude, JAMES, Richard William. Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients. In: NMCD. Nutrition Metabolism and Cardiovascular Diseases, 2009, vol. 19, n° 9, p. 613–619. doi: 10.1016/j.numecd.2008.12.005
Main files (1)
Article
accessLevelRestricted
Identifiers
ISSN of the journal0939-4753
545views
0downloads

Technical informations

Creation04/23/2012 1:23:54 PM
First validation04/23/2012 1:23:54 PM
Update time03/14/2023 5:25:32 PM
Status update03/14/2023 5:25:32 PM
Last indexation02/12/2024 7:59:58 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack